Evaluation of Pain Treatment After Total Knee Arthroplasty

Phase 4RecruitingNCT07538570

Vertex Pharmaceuticals Incorporated60 enrolled

Overview

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Pain

Interventions

SuzetrigineDRUG

Tablets for oral administration.

PlaceboDRUG

Placebo matched to SUZ for oral administration

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Locations (2)

Legent Orthopedic and Spine Hospital

Bellaire, Texas, United States

RECRUITING

Memorial Hermann Village Office

Houston, Texas, United States

RECRUITING

Outcomes

Primary Outcomes

Total Opioid Usage

Time frame: 24 hours to 168 hours after the first dose of study drug

Central Contacts

Medical Information

CONTACT

617-341-6777 medicalinfo@vrtx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.